Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

Bortezomib is a standard therapy of newly-diagnosed multiple myeloma and is also approved for relapsing disease, requiring the patients to travel to the outpatient-hospital (OH) once a week for several months. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation.

This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France: exclusive hospital-based Bortezomib administration versus combined administration in both OH and HaH.

Inclusion criteria

• Minimum age 18
• Enrolled in a social security scheme
• Diagnosis of multiple myeloma in first line or relapse
• Treatment plan including Bortezomib, adopted in a multidisciplinary meeting in a department of Hematology in Nancy (main investigator), Reims, Strasbourg University Hospitals or Metz-Thionville and Mulhouse local state-run hospitals
• The patients must have agreed to the treatment protocol and to take IV or PO associated drugs prescribed in addition to Bortezomib
• The patients must meet the 2003 eligibility criteria of the National Agency for Accreditation and Evaluation in Health (ANAES) for chemotherapy at home:

• Absence of severe adaptive or psychological disorders, ability to understand the protocol
• Absence of cognitive impairment
• Availability and agreement of the attending physician
• Home safety and hygiene
• Do not decline to participate in the research and share their personal data

Exclusion criteria

• Already participating in another trial
• Have a follow-up and/or treatment for another condition requiring a particular care during the Bortezomib treatment period